| Trial # | Type | Study Status | Status Date | Title |
|---|
| ASCO TAPUR | Advanced Solid Tumors | Open Active | 2021-10-20 | ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study |
| INST DARE | Breast Advanced | Open Active | 2021-08-10 | INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE) |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-08-21 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| SWOG S1706 | Breast Neoadjuvant | Open Active | 2023-09-08 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
| SWOG S1703 | Breast Other | Open Active | 2020-04-28 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
| SWOG S1912CD | Breast Other | Open Active | 2023-01-18 | SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT) |
| NRG-GI008 | GI Colorectal Adjuvant | Open Active | 2022-08-19 | NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease |
| Alliance A032001 | GU Ureter Advanced | Open Active | 2023-02-20 | Alliance A032001 MAIN-CAV: Phase III Randomized Trial Of Maintenance Cabozantinib And Avelumab Vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy In Patients With Metastatic Urothelial Cancer |
| ECOG-ACRIN EA3202 | Head And Neck Advanced | Open Active | 2023-12-05 | ECOG-ACRIN EA3202: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers |
| ALLIANCE A211901 | Head And Neck Other | Open Active | 2023-03-31 | ALLIANCE A211901: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions |
| SWOG S1803 | Hematology Myeloma | Open Active | 2024-02-29 | SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) |
| ECOG-ACRIN NHLBI-MDS | Hematology Other | Open Active | 2020-05-18 | ECOG-ACRIN NHLBI-MDS: THE NATIONAL MDS STUDY A Prospective, Multi-Center Cohort Supporting Research Studies in MDS Natural History |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-04-21 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-03-26 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
| DCP-001 | Supportive | Open Active | 2017-05-24 | DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| DCP-001A | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001B | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001C | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001D | Supportive | Open Active | 2017-05-24 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| Trial # | Type | Study Status | Status Date | Title |
|---|
| ASCO TAPUR | Advanced Solid Tumors | Open Active | 2021-10-20 | ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR) Study |
| ECOG-ACRIN EAY191 | Advanced Solid Tumors | Open Active | 2023-08-21 | ECOG-ACRIN EAY191: Molecular Analysis for Combination Therapy Choice (ComboMATCH) |
| Alliance A071401 | Brain Advanced | Open Active | 2022-01-14 | Alliance A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations |
| NRG Oncology NRG-BN003 | Brain Other | Open Active | 2017-10-20 | NRG Oncology NRG-BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma |
| Alliance A011801 | Breast Adjuvant | Open Active | 2021-05-17 | Alliance A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib |
| INST UNM 2004 | Breast Adjuvant | Open Active | 2022-05-27 | INST UNM 2004: Patient Understanding of the Benefit of Adjuvant Endocrine Therapy in Breast Cancer |
| INST DARE | Breast Advanced | Open Active | 2021-08-09 | INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE) |
| SWOG S2007 | Breast Advanced | Open Active | 2021-09-20 | SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases |
| CCTG MA.39 | Breast Neoadjuvant | Open Active | 2018-09-05 | CCTG MA.39: A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer |
| NRG-BR007 | Breast Neoadjuvant | Open Active | 2021-10-29 | NRG Oncology NRG-BR007: A Phase III Clinical Trial evaluating de-escalation of Breast Radiation for conservative treatment of Stage I, hormone sensitive, HER2-Negative, Oncotype recurrence score = 18 Breast Cancer |
| SWOG S1706 | Breast Neoadjuvant | Open Active | 2023-09-08 | SWOG S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrent with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer |
| ECOG-ACRIN EA1151 | Breast Other | Open Active | 2018-08-31 | ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST) |
| ECOG-ACRIN EA1151 | Breast Other | Open Active | 2022-09-29 | ECOG-ACRIN EA1151: Tomosynthesis Mammography Imaging Screening Trial (TMIST) |
| S2010 | Breast Other | Open Active | 2023-05-30 | SWOG S2010: A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN) |
| SWOG S1703 | Breast Other | Open Active | 2020-03-02 | SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer |
| SWOG S1912CD | Breast Other | Open Active | 2023-01-18 | SWOG S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery Of A Proactive Financial Navigation Intervention (CREDIT) |
| CIBMTR Protocol for a Research Database | Epidemiological | Open Active | 2017-06-29 | CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries |
| CIBMTR Protocol for a Research Database | Epidemiological | Open Active | 2020-11-10 | CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries |
| INST UNM 1521 - TCCP | Epidemiological | Open Active | 2017-12-08 | INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer |
| Alliance A022101 | GI Colorectal Advanced | Open Active | 2023-07-11 | Alliance A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) |
| NRG-GI008 | GI Colorectal Adjuvant | Open Active | 2022-08-18 | NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease |
| INST UNM 1803 | Epidemiological | Open Active | 2018-06-26 | INST UNM 1803: Enhancing Cancer Prevention and Control Pathways in the Zuni Pueblo-Native Health Initiative |
| ECOG-ACRIN EA2197 | GI Gastric Adjuvant | Open Active | 2021-05-28 | ECOG-ACRIN EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial |
| INST UNM 1809 | GI Colorectal Prevention | Open Active | 2018-12-27 | INST UNM 1809: Dissemination of a Colorectal Cancer Screening Program Across American Indian Communities in the Southern Plains & Southwest United States |
| Alliance A021806 | GI Pancreatic Adjuvant | Open Active | 2020-12-08 | Alliance A021806: A Phase III Trial Of Perioperative Versus Adjuvant Chemotherapy For Resectable Pancreatic Cancer |
| INST UNM 1603 | GI Other | Open Active | 2016-11-30 | INST UNM 1603: Enhancing Prevention Pathways Toward Tribal Colorectal Health |
| Alliance A022104 | GI Other | Open Active | 2024-08-27 | Alliance A022104: The Janus Rectal Cancer Trial: A Randomized Phase II/III Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy Regarding Clinical Complete Response and Disease-Free Survival in Patients with Locally Advanced Rectal Cancer |
| EA8212 | GU Other | Open Active | 2023-08-07 | ECOG-ACRIN EA8212: A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Nave High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) |
| SWOG S2104 | GI Pancreatic Adjuvant | Open Active | 2022-03-21 | SWOG S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumor |
| ECOG-ACRIN EA2192 | GI Pancreatic Adjuvant | Open Active | 2023-09-13 | ECOG-ACRIN EA2192: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation |
| NRG-GU009 | GU Other | Open Active | 2022-04-15 | NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT) |
| ECOG-ACRIN EA8134 | GU Other | Open Active | 2024-09-05 | ECOG-ACRIN EA8134: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) |
| NRG-GU010 | GU Prostate Neoadjuvant | Open Active | 2024-06-25 | NRG Oncology NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE) |
| NRG-GU011 | GU Other | Open Active | 2022-08-08 | NRG Oncology NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean) |
| NRG-GU009 | GU Other | Open Active | 2024-09-10 | NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT) |
| NRG-GY025 | GYN Endometrial Adjuvant | Open Active | 2023-10-13 | NRG Oncology NRG-GY025: A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma |
| SWOG S1937 | GU Ureter Advanced | Open Active | 2024-08-02 | SWOG S1937: A Phase III Randomized Trial of Eribulin (NSC #707389) With or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy |
| SWOG S1931 | GU RenalCell Adjuvant | Open Active | 2023-10-11 | SWOG S1931: Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial) |
| NRG-GY028 | GYN Endometrial Advanced | Open Active | 2023-05-04 | NRG Oncology NRG-GY028: A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer |
| NRG EAY191-N4 | GYN Endometrial Advanced | Open Active | 2023-08-21 | NRG EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial |
| ECOG-ACRIN EA3161 | Head And Neck Advanced | Open Active | 2023-10-13 | ECOG-ACRIN EA3161: A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC |
| UNM 1509 | GYN Other | Open Active | 2020-06-29 | INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies |
| NRG-GY026 | GYN Endometrial Neoadjuvant | Open Active | 2024-04-12 | NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-Zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma |
| INST 1310 | Head And Neck Advanced | Open Active | 2015-02-25 | (CLOSED TO IRB) INST 1310: An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma |
| ECOG-ACRIN EA3202 | Head And Neck Advanced | Open Active | 2023-12-05 | ECOG-ACRIN EA3202: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers |
| ECOG-ACRIN EA3191 | Head And Neck Advanced | Open Active | 2023-06-13 | ECOG-ACRIN EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features |
| RTOG 1216 | Head And Neck Advanced | Open Active | 2023-11-29 | Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck |
| NRG-HN009 | Head And Neck Advanced | Open Active | 2022-03-21 | NRG-Oncology NRG-HN009: Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| ALLIANCE A211901 | Head And Neck Other | Open Active | 2023-03-31 | ALLIANCE A211901: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions |
| INST UNM 1512 | Hematology Acute Leukemia | Open Active | 2018-05-23 | INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS |
| EA9152 | Hematology Acute Leukemia | Open Active | 2023-06-09 | ECOG-ACRIN EA9152: A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia |
| Pharm EZH-302 | Hematology Lymphoma Non-Hodgkins | Open Active | 2022-06-21 | Epizyme EZH-302: A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma |
| SWOG S1905 | Hematology Acute Leukemia | Open Active | 2023-12-19 | SWOG S1905: A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T- Cell Lymphoblastic Lymphoma (T-LBL) |
| ECOG ACRIN EAA181 | Hematology Myeloma | Open Active | 2021-12-17 | ECOG ACRIN EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation |
| SWOG S2114 | Hematology Lymphoma Non-Hodgkins | Open Active | 2024-04-09 | SWOG S2114: A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment For Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma |
| ECOG-ACRIN EA5182 | Lung NSCLC Advanced | Open Active | 2023-05-03 | ECOG-ACRIN EA5182: Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) |
| Alliance A151216 | Lung NSCLC Adjuvant | Open Active | 2016-05-09 | Alliance A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) |
| INST UNM 1903 | Hematology Other | Open Active | 2021-06-25 | INST UNM 1903: Collection of Apheresed Leukocytes for Research and Cell Therapy Process Development |
| SWOG S1803 | Hematology Myeloma | Open Active | 2023-12-08 | SWOG S1803: Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study) |
| SWOG S2302 | Lung NSCLC Advanced | Open Active | 2023-08-04 | SWOG S2302: Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer |
| SWOG S1900E | Lung NSCLC Advanced | Open Active | 2024-04-25 | SWOG S1900E: A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY) |
| SWOG LungMAP | Lung NSCLC Advanced | Open Active | 2019-03-14 | SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study) |
| DCP-001B | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001A | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001 | Supportive | Open Active | 2016-08-17 | DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) |
| Alliance A081801 | Lung SCLC Adjuvant | Open Active | 2022-03-15 | Alliance A081801: Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: ALCHEMIST Chemo-IO |
| SWOG S2205 | Supportive | Open Active | 2023-09-26 | SWOG S2205: ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Included Peripheral Neuropathy |
| DCP-001D | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
| DCP-001C | Supportive | Open Active | 2016-08-17 | Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)****This is for additional enrollments. Enter the Study Number in the patient status notes.*********** |
